JP2023526059A5 - - Google Patents

Info

Publication number
JP2023526059A5
JP2023526059A5 JP2022568830A JP2022568830A JP2023526059A5 JP 2023526059 A5 JP2023526059 A5 JP 2023526059A5 JP 2022568830 A JP2022568830 A JP 2022568830A JP 2022568830 A JP2022568830 A JP 2022568830A JP 2023526059 A5 JP2023526059 A5 JP 2023526059A5
Authority
JP
Japan
Prior art keywords
polynucleotide
lnp
peg
composition
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526059A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032438 external-priority patent/WO2021231854A1/en
Publication of JP2023526059A publication Critical patent/JP2023526059A/ja
Publication of JP2023526059A5 publication Critical patent/JP2023526059A5/ja
Pending legal-status Critical Current

Links

JP2022568830A 2020-05-14 2021-05-14 mRNA治療薬及びエフェクター分子を含むLNP組成物 Pending JP2023526059A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063024862P 2020-05-14 2020-05-14
US63/024,862 2020-05-14
US202163183119P 2021-05-03 2021-05-03
US63/183,119 2021-05-03
PCT/US2021/032438 WO2021231854A1 (en) 2020-05-14 2021-05-14 Lnp compositions comprising an mrna therapeutic and an effector molecule

Publications (2)

Publication Number Publication Date
JP2023526059A JP2023526059A (ja) 2023-06-20
JP2023526059A5 true JP2023526059A5 (cg-RX-API-DMAC10.html) 2024-05-24

Family

ID=76284222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568830A Pending JP2023526059A (ja) 2020-05-14 2021-05-14 mRNA治療薬及びエフェクター分子を含むLNP組成物

Country Status (6)

Country Link
US (1) US20230173104A1 (cg-RX-API-DMAC10.html)
EP (1) EP4149435A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023526059A (cg-RX-API-DMAC10.html)
AU (1) AU2021270587A1 (cg-RX-API-DMAC10.html)
CA (1) CA3182920A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021231854A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4562163A1 (en) * 2022-07-26 2025-06-04 ModernaTX, Inc. Engineered polynucleotides for temporal control of expression
CN115869332A (zh) * 2022-10-27 2023-03-31 北京新合睿恩生物医疗科技有限公司 递送至体内后在肝脏少表达的mRNA药物及其制备方法
EP4637786A2 (en) * 2022-12-22 2025-10-29 ModernaTX, Inc. Small nuclear ribonucleoprotein 13 polypeptides, polynucleotides, and uses thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025116441A1 (ko) * 2023-11-30 2025-06-05 주식회사 레나임 골관절염의 예방 또는 치료용 약제학적 조성물
WO2025255510A1 (en) * 2024-06-07 2025-12-11 The University Of Chicago Systems and methods for modulating rna

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
US5723332A (en) 1993-11-26 1998-03-03 British Technology Group Limited Translational enhancer DNA
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
EP2428570B1 (en) 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
JP5539962B2 (ja) 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ コレステロールを隔離するのに適したナノ構造体
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
US9163706B2 (en) 2012-08-29 2015-10-20 Greg SEBLANTE, SR. Sprocket box for increasing the gas mileage of a vehicle with an automatic transmission
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
US20160052352A1 (en) 2014-08-21 2016-02-25 The Goodyear Tire & Rubber Company Method of adhesion of rigid components to a tire
US9259829B1 (en) 2014-08-25 2016-02-16 Cougar Holdings, Llc Roofing and nail removal hammer
RS63625B1 (sr) * 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
GB2568255A (en) * 2017-11-08 2019-05-15 Evox Therapeutics Ltd Exosomes comprising RNA therapeutics
JP7556848B2 (ja) * 2018-09-14 2024-09-26 モデルナティエックス インコーポレイテッド mRNA治療薬を使用したがんを治療するための方法及び組成物

Similar Documents

Publication Publication Date Title
CN111971066B (zh) 脂质纳米颗粒
US20240218399A1 (en) Lipid compounds and lipid nanoparticle compositions
CN102824647B (zh) 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
JP2023537887A (ja) 脂質化合物及び脂質ナノ粒子組成物
JP2023531511A5 (cg-RX-API-DMAC10.html)
CN113631177A (zh) KRAS变体mRNA分子
JP2023532707A (ja) 脂質化合物及び脂質ナノ粒子組成物
CN118715201A (zh) 脂质化合物和脂质纳米颗粒组合物
CN116270534A (zh) 一种组织选择性递送核酸药物的类脂质纳米颗粒及其制备方法和应用
CN121568686A (zh) 用于皮肤疾病局部治疗的脂质纳米颗粒组合物
AU2023357989A1 (en) Rna constructs and uses thereof
WO2026103877A1 (zh) 脂质化合物和脂质纳米颗粒组合物
JP5931212B2 (ja) 弱酸性pH応答性ペプチド及び該ペプチドを含むリポソーム
TW202530174A (zh) 用於遞送的脂質化合物及脂質奈米顆粒
US20230092306A1 (en) Substance delivery carrier and composition
CN103509066B (zh) 一种含有唾液酸片段的脂质衍生物及其应用
CN118580157A (zh) 一种靶向肺部的氨基酸脂质及其形成的脂质纳米递送系统
WO2024022263A1 (zh) 脂质化合物和脂质纳米颗粒组合物
CN116407625A (zh) 一种用于增强核酸免疫效力的脂质纳米颗粒及其制备方法和用途
HK40127068A (en) Lipid nanoparticles
WO2026092641A1 (zh) 一种调控AGT基因表达的siRNA及其用途
TW202440929A (zh) 用於感染性疾病的組合物和方法
WO2026085468A1 (en) Ionizable lipid compounds comprising amidine crosslinkers or aryl-alkyl disulfides and lipid nanoparticles (lnps) comprising the same
TW202412818A (zh) 用於暫時控制表現之經工程化多核苷酸
JP6495995B2 (ja) 脂質粒子および核酸送達キャリア